Memorial Sloan Kettering Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).

1,884 total trials 327 currently recruiting 1104 completed early-phase tilt top decile by trial count

Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.

Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.

Top-decile sponsor footprint

Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

1,884 total, page 23 of 38

COMPLETED NA

A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression

NCT01604512

COMPLETED

Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer

NCT01591772

COMPLETED Phase 1

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

NCT01579994

COMPLETED Phase 2

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

NCT01589094

COMPLETED Phase 1

Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT01579929

COMPLETED Phase 3

Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection

NCT01596283

COMPLETED

Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer

NCT01558648

COMPLETED Phase 2

Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium

NCT01551030

COMPLETED Phase 2

Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

NCT01558661

COMPLETED Phase 2

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

NCT01522768

COMPLETED NA

Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer

NCT01542021

COMPLETED Phase 1

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

NCT01543659

COMPLETED

Doctor-Patient Communication About Colorectal Cancer Screening

NCT01534923

COMPLETED NA

MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning

NCT01534104

COMPLETED

Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy

NCT01551433

COMPLETED NA

A Pilot Study to Assess the Amnesic Properties of Propofol in Pediatric Patients

NCT02278003

COMPLETED

Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Head and Neck, and Prostate Cancers

NCT01535898

TERMINATED

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

NCT01532232

COMPLETED Phase 2

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01508312

COMPLETED Phase 3

Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma

NCT01491698

COMPLETED Phase 2

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

NCT01492673

COMPLETED Phase 1

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

NCT01502592

COMPLETED

International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center

NCT01504152

COMPLETED Phase 1

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

NCT01484093

COMPLETED

Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations

NCT01482923

COMPLETED

Prognostic Value of Rb-82 PET Myocardial Perfusion Imaging

NCT01474577

COMPLETED

Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer

NCT01471483

COMPLETED

Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma

NCT01474564

COMPLETED

Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients

NCT01466946

COMPLETED

Patient Factors Impacting Adherence to Oral Chemotherapy

NCT01487343

COMPLETED

Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging

NCT01482741

TERMINATED

Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging

NCT01473693

TERMINATED Phase 2

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

NCT01474551

TERMINATED

Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients

NCT01473680

COMPLETED Phase 2

Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance

NCT01463670

COMPLETED Phase 1

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

NCT01456104

COMPLETED

Feasibility and Psychometric Properties of Paper vs. Web vs. Automated Telephone Administration of Patient Reported Outcome Surveys

NCT01458509

COMPLETED Phase 2

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

NCT01443078

TERMINATED Phase 1

BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

NCT01453595

COMPLETED NA

Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer

NCT01442051

COMPLETED Phase 2

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

NCT01437709

COMPLETED

Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

NCT01436240

COMPLETED

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

NCT01423734

COMPLETED Phase 1

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

NCT01416974

COMPLETED Phase 1

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

NCT01419834

COMPLETED NA

Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant

NCT01416246

TERMINATED Phase 1

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

NCT01418001

COMPLETED Phase 1

Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

NCT01392209

COMPLETED Phase 1

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

NCT01393509

COMPLETED Phase 2

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

NCT01399918

← Previous Page 23 of 38 Next →

Phase Distribution

PhaseTrial count
Phase 1 461
Phase 2 640
Phase 3 67
Phase 4 8

What is open in the Memorial Sloan Kettering Cancer Center pipeline

327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).

Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (98 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.